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Commentary
Epigenetics describes mechanisms of 
  mitotically heritable changes in gene expres-
sion that occur via means other than DNA 
sequence alteration. The proper establishment 
of the individual cellu  lar epi  genetic code is 
critical for proper develop  ment. Further, it 
has been hypothesized that improper estab-
lishment of the epi  genetic code can translate 
to disease development, including loss-of-
imprinting disorders and cancer (where this 
scientific field is most significantly developed) 
and, more recently, disease-associated states 
occurring as the result of epi  genetic altera-
tions of the germline, termed “epimutations” 
(Bennett et al. 2010; Dobrovic and Kristensen 
2009; Hitchins 2010; Wong et al. 2010). 
The establishment of the epi  genetic state that 
will guide development begins immediately 
after fertili  zation when the nascent organism 
loses all DNA methylation marks and resets 
the entirety of its epi  genetic condition in a 
cell-type–specific fashion in order to dictate 
somatic development. Hence, the fetal envi-
ronment is generally accepted to be crucially 
important in the genesis of proper epi  genetic 
marks and in the subsequent orchestration of 
complex cellular and organismal differentia-
tion. Further, it is likely that the intra  uterine 
environment’s hypothesized role in affecting 
health and disease later in life results from 
perturbation of epi  genetic developmental 
  programming (Tamashiro and Moran 2010).
The repertoire of epi  genetic mechanisms is 
complex and not yet completely understood. 
However, histone proteins, which inter  act 
with DNA to form chromatin, are central 
participants in epi  genetic regulation. Post-
translational modification of histone proteins 
is thought to alter the structure of chroma-
tin, allowing various processes to occur that 
have profound consequences for the utility, 
parsimony, and general long-term viability of 
the genome, including transcription, DNA 
repair, DNA replication, and gene silencing. 
The expression or repression of the genome 
is marked by appropriately modified his-
tones, and this is reflected at the DNA level 
as the absence or presence of CpG dinucleo-
tide methylation. CpG dinucleo  tides are sig-
nificantly under  represented in the genome 
(likely due to the spontaneous deamina  tion 
of cytosine), but when present they are often 
concentrated in CpG islands. CpG islands are 
associated with almost 50% of all described 
genes, and most are located in gene promoter 
regions. DNA methylation, as a representative 
of epi  genetic regulation, is significantly more 
amenable to measure  ment in epidemiologic 
studies than are histone modifications, and 
this is reflected in the emerging literature. The 
simplicity of measuring DNA methylation 
is attributable to the use of sodium bisulfite 
conversion, a chemical process that deami-
nates unmethylated cytosines to uracil while 
retaining methylated cytosines (Herman et al. 
1996). DNA methylation determination is 
then made by distinguishing between a C or 
T residue, and any geno  typing platform may 
be used to assess methylation after bisulfite 
conversion of the DNA. With the advent of 
more affordable high-throughput sequencing 
technologies, other methods not relying on 
sodium bisulfite, such as meth  ylated DNA 
immuno  precipitation, are beginning to be 
used in population-based contexts and will 
likely grow in utility.
The importance of maintaining the epi-
genetic state of individual genes is most clearly 
illustrated for the occurrence of cancer. A solid 
body of research describes a vast array of tumor 
suppressor genes inactivated by a process that 
includes gene promoter hypermethylation in 
almost every type of cancer. However, even 
before we understood the role of tumor sup-
pressor promoter hypermethylation, research-
ers recognized that solid tumors are heavily 
hypomethylated relative to their normal tissue 
counterparts. This genomic or global hypo-
methylation is now believed to occur early in 
tumori  genesis, even in pre  cancerous lesions 
(Pufulete et al. 2003; Suter et al. 2004), 
potentially accelerating the genomic instability 
currently thought to be necessary for cancer 
development. Yet “global methylation” is a 
vague term, used to interchangeably refer to 
various measures of cytosine methylation of 
the genome overall, of repetitive elements, 
or of multiple gene regions. In fact, these are 
potentially non  comparable measures arising 
from distinct cellular processes; therefore, 
greater clarity is called for when examining 
and reporting these disparate measures.
Measuring Global Methylation
Because there are critical links between 
genomic hypomethylation and pathogenesis, 
there is a growing research interest in deter-
mining whether changes to the global status 
of DNA methylation is related to the envi-
ronment and whether these changes can be 
biomarkers of disease. A number of meth-
ods have been developed to quantify global 
methyl  cytosine content of DNA samples. 
Total methylcytosine can be directly meas-
ured using chromatographic methods after 
digestion of the DNA into single nucleotides. 
Although these methods are highly quanti-
tative, they generally require large amounts 
of DNA and highly specialized equipment 
and are generally difficult to standardize for 
use on large sample collections such as those 
collected in an epidemiologic context. Thus, 
many research groups have opted for poly-
merase chain reaction (PCR)-based methods 
that capitalize on bisulfite modification chem-
istry. Weisenberger et al. (2005) described 
methylation at satellite repeats, LINE-1 (long 
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interspersed nuclear element-1), and ALU 
elements as being reasonably well correlated 
with total methyl  cytosine content using a 
quantitative PCR-based approach. This effort 
followed a report by Yang et al. (2004) that 
described the initial use of bisulfite sequencing 
of LINE-1 and ALU elements to determine 
global methylation. These studies prompted 
a new line of investigation using quantitative 
methylation at repetitive elements in lympho-
cytes to evaluate the association of variation 
in environmental exposures with levels of 
what became accepted as a measure of global 
DNA methylation. For example, many groups 
have evaluated global methylation and air 
pollution, with most of the studies observing 
decreased methylation among exposed indi-
viduals (Baccarelli et al. 2009; Bollati et al. 
2007; Tarantini et al. 2009), with the excep-
tion of one investigation of coke oven workers 
who had elevated global methylation relative 
to controls (Pavanello et al. 2009). It should 
be noted that in a recent study, Choi JY et al. 
(2009) were unable to replicate the correla-
tion between total methylcytosine content and 
LINE-1 methylation measured with bisulfite 
pyrosequencing. 
Methylation at LINE-1 and ALU. If the 
methylation status of LINE-1 and ALU ele-
ments is to be used to signify global methyl-
cytosine content, it is important to understand 
what these elements represent and why they 
are methylated in non  diseased tissues. Nearly 
half the DNA content of the human genome 
consists of repetitive sequences of DNA: trans-
posons, retro  transposons, and endogenous 
retroviruses. Typically these elements are non-
transcribed and maintained as hetero  chromatin 
(and hence characterized by hyper  methylation). 
Most of these elements are devoid of phenotype 
through truncation or other inactivating muta-
tions. Activation of transposons, however, can 
initiate or enhance disease processes, including 
carcino  genesis. In fact, transposons have been 
exploited as tools for mammalian muta  genesis 
and forward genetics screens (Largaespada 
2009; Ostertag and Kazazian 2001; Starr et al. 
2009). LINE-1 elements are retro  transposon 
sequences, whereas ALU elements are short 
interspersed nuclear elements. Together, the 
LINE and ALU sequences comprise approxi-
mately 30% of the genome (Miki 1998). Their 
ubiquitous presence genomically, combined 
with their relatively conserved sequence and 
propensity of methyl-CpG targets, highlights 
their appeal as a representative measure of 
global methylation.
However, further examination of these 
sequences reveals significant technical limita-
tions that must be considered carefully. There 
are approximately 500,000 LINE-1 elements 
in the genome, and it is unknown how many 
of these are of full length (6 kb), consisting 
of a) a 5´ untranslated region (UTR) with 
an internal RNA polymerase II promoter, 
b) two open reading frames encoding an RNA 
binding protein and elements necessary for 
retro  transposon activity, and c) a 3´ UTR con-
taining a polyadenylation signal (Cordaux and 
Batzer 2009). The CpG sequence targeted by 
pyro  sequencing for LINE-1 is in the 5´ region 
(usually three to six sites); however, the 5´ end 
of the sequence tends to be deleted (but with 
unknown frequency) except in the more active, 
evolutionarily newer sequences. Therefore, with 
this assay we cannot, with accuracy, know how 
many elements we are evaluating or whether 
this number is similar across samples or indi-
viduals. Simply put, the denominator in this 
measurement is not known and is likely not 
constant. For example, sex is associated with 
LINE-1 methylation (Wilhelm et al. 2010; Zhu 
et al. 2010). One cannot know (with certainty) 
whether this sex difference is attributable to 
copy number variation in LINE-1 on the X 
and Y chromosomes or a sex hormone effect 
that affects methylation. Further complicating 
this measurement problem is the knowledge 
that a subset of LINE-1 elements (possibly up 
to 80) is transposon competent, meaning that 
when these competent sequences are unmethy-
lated (i.e., immediately after fertilization) they 
may generate new LINE-1 sequences by rein-
tegrating into the genome. In fact, evidence is 
building that humans are highly polymorphic 
for LINE-1 sequences (Ewing and Kazazian 
2010); therefore, it is almost certain that popu-
lations are evolving differently with regard to 
the distribution of LINE-1 sequences.
Assessment of ALU methylation is sub-
ject to many of the same concerns as LINE-1. 
Unlike LINE-1, ALU uses an internal RNA 
polymerase III promoter and lacks any cod-
ing sequence. Instead, for retrotransposition, 
ALU elements require the use of the retrotrans-
position machinery of LINE-1 (Dewannieux 
et al. 2003). Therefore, the meas  ured CpGs at 
ALU are likely under different selective pres-
sures relative to the inactive and active LINE-1 
sites. In fact, the quantitative assessment of 
DNA methylation at ALU is consistently about 
one-third to one-fourth the level of methy-
lation at LINE-1. This supports the notion 
that methylation at LINE-1 and ALU might 
measure something quite different. Similar to 
LINE-1, ALU is highly polymorphic, again 
leading to concerns regarding population dif-
ferences in the number and location of the 
repeats. Finally, DNA methylation occurs 
throughout the genome in a sequence-context–
dependent fashion, and the extent to which 
regional sequence context might affect differ-
ent measures of DNA methylation remains to 
be assessed.
Finally, the degree of methylation at repeat 
regions reflects the “stability” of an individ-
ual’s genome because repeat sequences are 
recognized, in many cases, to harbor known 
fragile regions and disease-associated expres-
sion (Belancio et al. 2009; Dion et al. 2008; 
Kulis and Esteller 2010). There is little direct 
evidence that the known hypo  methylation 
that occurs in tumor cells is responsible for the 
commonly observed genomic instability that 
can similarly be a hallmark of the malignant 
phenotype, although this concept is largely 
becoming accepted as an important thesis.
Despite these limitations, there are consis-
tent epidemiologic observations in the litera-
ture that support methylation at LINE-1 and 
ALU as meaningful biomarkers. The limited 
number of published assessments of these 
two distinct measures in the same individ-
ual in the same tissue suggest that the meas-
ures are weakly but significantly correlated 
(Chalitchagorn et al. 2004; Choi SH et al. 
2009; Weisenberger et al. 2005), although few 
data describe variation across tissues or from 
the same individual at various time points.
Evidence that DNA methylation at 
LINE-1 and ALU is a biomarker of environ-
mental exposures and disease states. Early 
epidemiologic studies assessing DNA methyla-
tion at LINE-1 and ALU assumed that these 
meas  ures should both reflect the state of global 
methylation. In fact, the assumption that the 
level of methyla  tion at DNA repeat sequences 
reflected some individually relevant set point 
with “global” implications was largely untested. 
However, the average methylation at these 
repetitive elements in blood cells is correlated 
with aging (Bollati et al. 2009; Jintaridth and 
Mutirangura 2010; Kim KY et al. 2010; Zhu 
et al. 2010); race/ethnicity (Terry et al. 2008); 
and many environmental exposures, including 
air pollution (Baccarelli et al. 2009; Bollati 
et al. 2007; Tarantini et al. 2009), metal expo-
sure (Pilsner et al. 2010; Wilhelm et al. 2010; 
Wright et al. 2010), persistent organo  pollutants 
(Kim KY et al. 2010; Rusiecki et al. 2008), and 
alcohol consumption (Choi JY et al. 2009; 
Zhu et al. 2010). Global methylation is also 
associated with disease states, including many 
cancers (Cho et al. 2010; Choi JY et al. 2009; 
Hou et al. 2010; Moore et al. 2008; Ting 
Hsiung et al. 2007; Wilhelm et al. 2010), 
stroke (Baccarelli et al. 2010; Kim M et al. 
2010), and heart disease (Baccarelli et al. 2010; 
Kim M et al. 2010; Smolarek et al. 2010). 
Interestingly, there seems to be little coher-
ence in the relation  ship of LINE-1 methylation 
with methylation at ALU repeats in revealing 
associations of exposures or disease states. This 
fact has received little attention and remains 
essentially unexplained. For example, there is 
a consistent relationship between persistent 
organic pollutant exposure and hypomethyla-
tion at ALU but not at LINE-1 (Kim KY et al. 
2010; Rusiecki et al. 2008), and the reason for 
this dichotomy is not understood.
Inconsistencies in the literature on the 
global methylation–disease relationship may Nelson et al.
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be attributable to measurement method. For 
example, in two well-regarded studies, risk of 
stroke is associated with either global hypo-
methylation, as assessed by LINE-1 bisulfite 
pyro  sequencing (Baccarelli et al. 2010), or 
global hypermethylation, as assessed using 
MethyLight at ALU and SAT2 (spermidine/
spermine N1-acetyltransferase family mem-
ber 2) (Kim M et al. 2010). However, for 
other diseases (e.g., bladder cancer) the rela-
tionship between global methylation and dis-
ease is clear. In initial work in the Spanish 
Bladder Cancer Study, Moore et al. (2008) 
assessed blood cell methylation using a combi-
nation of high-performance capillary electro-
phoresis and methylation-sensitive restriction 
enzyme digestion and densitometry. These 
authors reported very elevated bladder can-
cer risks in non  smokers with low levels of 
DNA methylation. In subsequent work in 
the New Hampshire bladder cancer study, 
Wilhelm et al. (2010) reported consistent 
results using pyrosequencing of LINE-1 from 
blood-derived DNA. In more recent work in 
the Shanghai Bladder Cancer Study, again 
measuring DNA methylation at LINE-1 using 
pyrosequencing, Cash et al. (2011) reported 
additional evidence of the bladder cancer 
risk associated with lower levels of DNA 
  methylation (  primarily in non  smokers). 
The first prospective studies of the asso-
ciation of repetitive element DNA methy-
lation and disease have been reported only 
recently. Kim M et al. (2010) demonstrated 
that increased methylation, meas  ured using 
ALU and SAT repeat regions, was associated 
with cardio  vascular disease risk. Baccarelli 
et al. (2010) found that LINE-1 DNA methy-
lation level (assessed using pyrosequencing) 
prospectively predicts ischemic heart disease. 
In addition, there is a significant correlation 
between maternal and newborn LINE-1 lev-
els, consistent with other work suggesting that 
heritability of LINE-1 methylation level may 
be sex specific (Kile et al. 2010; Mirabello 
et al. 2010). This highlights (although clearly 
does not in any way prove) the possibility that 
some component of LINE-1 DNA methyla-
tion level may be genetically determined.
Utility of animal models. Important work 
in animals addresses some aspects of these 
questions. Work in the agouti mouse model 
has confirmed that environmental alterations 
during pregnancy (most prominently in diet) 
affect epi  genetically determined phenotypes 
in offspring, reportedly through the altered 
methylation status of intra  cisternal A-particle 
(IAP) retro  transposons upstream of the ago-
uti locus (Waterland and Jirtle 2003; Wolff 
et al. 1998). In vitro and in vivo animal stud-
ies also have shown that global methylation 
is a consequence of arsenic exposure (Davis 
et al. 2000; Zhao et al. 1997), although this is 
generally measured using methods that are not 
analogous to assessing repeat methylation in 
humans and at exposures that are not relevant 
to human exposures. Although these animal 
models do not prove that global methylation 
effects lead to disease outcomes caused by arse-
nic, it may remove questions of reverse causal-
ity and provide insight on the mechanism of 
arsenic’s toxicity.
However, humans and rodents have impor-
tant systematic differences regarding repeat 
regions. Interspersed repetitive elements make 
up some 45% of the human genome (Lander 
et al. 2001) compared with approximately 
38% of the rodent genome (Waterston et al. 
2002). Retrotransposons can be divided into 
two distinct groups: those containing long-
terminal repeats (LTRs) and others (so-called 
non-LTR retro  elements). LTR retrotranspo-
sons have been inactive in humans for mil-
lions of years but make up approximately 8% 
of the human genome (Lander et al. 2001). 
This contrasts with rodent genomes, in which 
the LTR elements are active and are known 
to be responsible for significant numbers of 
germline-associated mutations (reviewed by 
Maksakova et al. 2006). Actively transposing 
repeats are believed to be responsible for about 
10% of mutations in rodents (Maksakova 
et al. 2006), unlike in humans, where this 
number is considerably smaller (Belancio et al. 
2009). The activity of transposable elements 
has often been assumed to be confined to the 
developing embryo and possibly to cancer cells 
in humans (Branciforte and Martin 1994; 
Ergun et al. 2004; Martin 1991; Martin and 
Branciforte 1993). However, LINE-1 proteins 
(ORF1 and ORF2) can be found in human 
somatic tissues (Ergun et al. 2004). Further, 
somatic LINE-1 retro  transposition also occurs 
in transgenic mouse models (Babushok et al. 
2006; Kano et al. 2009), and transgenic mice 
have signifi  cantly greater LINE-1 mobiliza-
tion in somatic tissues than in the germline 
(An et al. 2008; Babushok et al. 2006). Thus, 
rodents and humans both display repeat region 
hyper  methylation but have evolutionarily very 
different systems mediating these epi  genetic 
changes. Hence, care is needed when general-
izing observations in rodents to humans.
Surrogate tissues. For epidemiologists, 
there is an obvious question posed by the 
litera  ture: What are we measuring with these 
different assays? As important as this ques-
tion is, assessing global methylation raises yet 
another, more classic problem: Is global DNA 
methylation (measured in each of these seem-
ingly distinct assays) different in different tis-
sues? Of course, it is unclear how to actually 
study methylation levels in cells from inac-
cessible tissue. Often we turn to surrogate 
tissues, such as circulating blood lymphocytes 
or sloughed buccal cells. Using these surro-
gate tissues to evaluate gene-specific methyla-
tion is complicated by the fact that epi  genetic 
marks can occur in a tissue-specific manner 
(Christensen et al. 2009).
Although tissue-associated differences in 
DNA repeat methylation have been described 
in some studies, exhaustive research remains to 
be performed. The current literature supports 
the assertion that there are tissue differences 
in LINE-1 and ALU DNA methylation levels, 
but these are not large, and they may be influ-
enced by the environ  ment (Chalitchagorn et al. 
2004; Choi SH et al. 2009; Wu et al. 2011a, 
2011b; Zhu et al. 2010). The mechanism(s) 
responsible for these tissue-specific differences 
is unknown. Recent work shows that LINE-1 
retro  transposition can occur in a tissue-specific 
fashion (Muotri et al. 2010), although whether 
this would be sufficient to affect the measure 
of LINE-1 DNA methylation overall is not 
known. Because it is clear that different tissue 
develop  ment is attributable to differential gene 
expression, born of distinct epi  genetic profiles 
(Christensen et al. 2009), differences in repeat 
region methylation might be the result of set 
point differences that are determined in utero 
and are tissue specific. Alternatively, they could 
be differentially induced over time by changes 
in the local environment of each tissue, or they 
might be affected by differences (environ  mental 
or genetic) in maintenance DNA methyltrans-
ferase or de novo DNA methyltransferase. It 
should be noted that DNA methylation at 
the fifth carbon position of cytosine is cova-
lently bound, mitigating concerns that this 
has limited stability. In sum, detailed experi-
ments should be conducted in order to further 
understand the contribution of each of these 
possibilities to the measureable levels of repeat 
region DNA methylation, because this will 
enhance the interpretability of these measures.
There is evidence that the spectrum of cell 
types present in peripheral blood affects meas-
ures of LINE-1 and ALU DNA methyla  tion 
(Zhu et al. 2010). This is consistent with the 
notion that tissues are different with respect 
to LINE-1 methylation in that the white 
blood cell lineages are distinct and their mat-
uration and differentiation are driven by epi-
genetic means (similar to other tissues). This 
clearly implies that studies using peripheral 
blood as the tissue of interest for measuring 
global methylation must take into account 
the dynamic nature of the profile of the tissue 
and any somatic condition known to alter this 
profile. Of course, because white blood cells 
infiltrate many tissues, cellular hetero  geneity 
is almost certain to be a feature of any tissue 
measure that is used in epidemiologic study. 
Variation or even bias associated with these 
measures must be considered in study design 
and analysis.
Additional work is needed to describe the 
quantitative variation in the different meas-
ures of global methylation. The factors that 
affect variation in global methylation are not Global methylation biomarkers
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completely understood, and the kinetics, 
relative magnitude, and precise relationship 
of different measures of DNA methylation 
among tissues remain to be well defined. 
More investigation will help us to understand 
how well alterations of DNA methylation at 
repeat regions (and other global methylation 
sites) in an accessible tissue (e.g., blood) reflect 
processes that are occurring in other tissues or 
represent systemic changes allowing for infer-
ence on disease risk or prevention. Clearly, the 
known disease associations of altered imprint-
ing and epimutation suggest that some disease 
processes may manifest in all cells and hence 
be quite detectable in blood.
Establishment of methylation marks. 
Inherent in the understanding that there is 
reproducible tissue specificity in meas  ures of 
methylation is the concept that methylation 
marks, then, must have been initially differ-
entially established during tissue differentia-
tion and subsequent development. The “fetal 
origins” or “developmental origins and health 
and disease” hypothesis was developed from 
a series of studies that demon  strated an asso-
ciation between measures of birth size and 
long-term chronic disease risk. Most of these 
studies focused on cardio  vascular disease and 
metabolic syndromes (Barker and Bagby 
2005; Barker and Osmond 1988; Barker et al. 
1989), linking ante  natal environ  mental fac-
tors, including diet, xeno  biotic exposures, 
stress, and lifestyle factors, to altered fetal 
growth and—through programming—to per-
manent biological and physiologic changes 
in the offspring. The mechanism of this reli-
ably observed phenomenon is necessarily epi-
genetic in nature. This link between antenatal 
exposures and altered phenotypes supports the 
hypothesis that observed variable set points of 
global methylation in specific tissues is related 
to the in utero environment. Further, it is 
likely that these differences can be detected 
at birth and that the environment encoun-
tered post  natally affects variability, although 
research is only beginning to examine this vari-
ability and the effects of various periods of life 
on epi  genetic regulation.
The variability in the levels of methyla-
tion globally or at specific repetitive elements 
defined at birth may, in fact, explain the 
regional differences in overall levels of methyla-
tion of LINE-1 that have been observed in 
various studies but have received little discus-
sion. For example, Zhu et al. (2010) examined 
LINE-1 methyla  tion related to exposures in five 
studies from Europe and the United States; the 
largest observed effect was study site, despite 
the fact that a single laboratory conducted 
LINE-1 methylation measurements. Similarly, 
comparing data from two bladder cancer stud-
ies, one in New Hampshire (Wilhelm et al. 
2010), and one in Shanghai, China (Cash et al. 
2011), again collected from a single laboratory, 
Wilhelm et al. (2010) demon  strated significant 
differences in the levels of LINE-1 methylation 
between populations. The under  lying etiol-
ogy of these differences is not clear, although 
it could be related to genetic differences in 
the populations or differences in in utero or 
post  natal environments encountered by these 
individuals. Although such differences can be 
accounted for in multi  variable models, under-
standing the nature of these differences may be 
critically important to interpreting the biologi-
cal meaning of exposure- or disease-associated 
changes in LINE-1 or other repetitive element 
measures of global methylation.
Other repetitive sequences. LINE-1 and 
ALU are not the only repetitive elements that 
have been used as determinants of global 
methylation. DNA sequence repeat regions are 
found across the genome and include satellite 
repeated sequences found in tandem that have 
arisen as a result of amplification of simple 
repeats (these include SATα in centromeric 
regions, and SAT2 and SAT3, which are sub-
telomeric) (Jordan et al. 2003; Lander et al. 
2001). The DNA transposons are the oldest 
type of transposable element and are largely 
completely degenerate as a result of deletion 
and truncation events over time. However, 
the SAT elements are small (averaging 
215 bp), a few remain active in the genome, 
and their methylation has been poorly stud-
ied in carcino  genesis (Alexander et al. 2010). 
Although LINE-1 and ALU are considered 
retro  transposons, others of the LTR type, con-
sidered endogenous retroviruses, have been 
used to examine genomic methylation state. 
More than 400,000 of these retroviral elements 
encompass 8% of the human genome (Lander 
et al. 2001). The inappropriate activation of 
these elements has been linked to various can-
cers, particularly Hodgkin’s lymphoma, as well 
as in auto  immune diseases such as systemic 
lupus erythematosus, although their causal-
ity for disease is not yet established (Balada 
et al. 2009; Florl et al. 1999; Januchowski 
et al. 2004; Menendez et al. 2004; Ogasawara 
et al. 2003; Okada et al. 2002; Ruprecht et al. 
2008; Stacey and Sagulenko 2010; Stengel 
et al. 2010). The LTR elements have been 
subject to limited study, but their potential for 
activation associated with hypomethylation 
and the determinants of that hypo  methylation 
remain largely unexplored (Gimenez et al. 
2009; Huh et al. 2008; Schulz et al. 2006).
Conclusions and Research 
Needs
Current research strongly suggests that assess-
ment of the level of DNA methylation at 
repeat regions and in the genome as a whole 
is poised to reveal crucially important bio-
logical processes that are causal or contrib-
utory in numerous disease states. There are 
several caveats, however, to moving this line 
of research forward, specifically regarding 
the molecular phenotype of these alterations, 
their link to disease processes, and method-
ologies capable of distinguishing differences 
in methylation extent from inherent genomic 
variability of these elements.
Environmentally induced alterations in 
DNA methylation at repeat sequences may 
have specific and definable phenotypic con-
sequences. One can speculate that either sto-
chastic or targeted hypo  methylation at repeats 
could activate small noncoding RNAs that are 
normally silent. This activation could then 
induce or enhance toxi  cant action. Indeed, 
quantifying or meas  uring this kind of biologi-
cal effect might easily differ depending upon 
the method used to assess hypo  methylation 
(e.g., some methods interro  gate the impor-
tant small RNA sequences, whereas others do 
not), consistent with the current literature. 
Alternatively, global hypomethylation may act 
chiefly to destabilize the genome. Instability 
might contribute to numerous important 
disease phenotypes, particularly if it is tar-
geted. In either of these constructs, hypo-
methylation at repeat regions would have very 
different pheno  typic consequences than epi-
genetic alteration of specific genes but could 
potentially represent an important part of 
the toxi  cant mode of action. In our effort to 
better understand global hypomethylation, 
we must first define the biological mecha-
nisms that control and define this potentially 
very important phenomenon. At present, we 
would argue that there is really no way to 
generate a reasonable consensus on the mean-
ing of “global DNA methylation.” Although 
this concept is attractive and potentially use-
ful, it really has no transcendent meaning. 
As we move toward intensive research of this 
concept, it seems prudent to use more speci-
ficity in describing the manner in which we 
assess DNA methylation.
In addition, there are few prospective 
studies and a clear need for biological experi-
mental follow-up to actually determine the 
mechanism and import of the observations 
that the environment alters the epi  genetic 
state. Examinations determining how meas  ures 
of these alterations in surrogate tissues relate 
to changes in the disease-targeted tissues will 
provide a clearer under  standing of whether it 
is the changes in target tissues or potentially in 
the surrogate tissues themselves that are play-
ing a contributory role in disease. Until we 
have an appropriate grasp on the under  lying 
meaning of the variability of these measures 
and the factors effecting their measure  ment, 
we cannot make conclusive or useful recom-
mendations to affect these measures for the 
sake of disease prevention or treatment efforts.
Assessing LINE-1 methylation with the 
current PCR-based protocols is perfected 
to the point that very large studies are now Nelson et al.
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possible; this is an exciting and important 
development. However, the assays have some 
unique features. The LINE-1 assays yield a 
measure that is restricted to LINE-1 regions 
that have an intact internal promoter. Recent 
research is probing human and model systems 
to define the likely significant contribution 
of active retro  transposition (occurring during 
blasto  cyst develop  ment) to disease (Dean et al. 
2005). Active elements may have a biology 
that is quite unique, and the selective assess-
ment of these regions may result in the study 
of a distinct group of pheno  typically unique 
regions. That is, inactive LINE-1 repeats that 
are not transposition competent or are trun-
cated may behave in a systematically differ-
ent manner from the active sequences. This 
bias in our assessment of DNA methylation 
may be critically important and drive some 
of the associations observed in epidemiologic 
inquiry. Some form of pheno  typic selection 
also might explain the differences observed 
in studying ALU and LINE-1 regions in the 
epidemiologic context (and potentially even 
help to explain within-person variability in 
these measures). Hence, designing assays that 
can differentially assess DNA methylation in 
active and non  active LINE-1 regions would 
be revealing. Clearly, we are in urgent need 
of a better understanding of the relationship 
of LINE-1 methylation levels with active   
retrotransposition-competent compared with 
retrotransposition-incompetent regions, with 
the idea that this may result in some impor-
tant form of phenotypic selection.
As noted above, there is good evidence 
that LINE-1 regions are poly  morphic in 
humans. The impact of this polymorphism 
on health and disease is essentially unstudied. 
As we continue to assess the epi  genetics of the 
LINE-1 region, it is important that we devise 
methods to assess the extent and impact of this 
variation. Indeed, more assessment of the epi-
demiologic importance and potential variation 
at the other DNA repeat regions would also be 
of interest. Limited study of tandem repeats 
and LTR transposons has been reported, but 
there is currently little systematic compari-
son of these measures in humans. Because 
genome  wide CpG-specific array-based assays 
are now more commonly used in population- 
based studies, there is also a need to deter-
mine whether data from these arrays can 
be used to assess genome  wide methylation. 
Understanding the coverage of the arrays and 
selection of sites for examination is critical, 
because these meas  ures may reflect under  lying 
selective pressure for some level of methyla-
tion dependent on the sites measured. Clearly, 
multi  disciplinary approaches spanning epide-
miology, genetics, biostatistics, and bioinfor-
matics are needed to best study methylation 
as a marker of exposure and disease and to 
interpret data from these examinations.
In summary, we believe the term “global 
methylation” should be reserved for non-
  sequence-dependent determinations (specifi-
cally analytical measures) of methyl  cytosine 
content. Other quantitative assessments of 
DNA methylation dependent on sequence 
content should be described specifically accord-
ing to this attribute and interpreted relative to 
possible pheno  typic consequences.
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